MMSI · Merit Medical Systems, Inc.

Merit delivered strong Q1 2026 financial results, with GAAP revenue of $381.9 million (+7% YoY) and GAAP EPS of $0.68 (+39% YoY), driven by solid performance across both Foundational (+6%) and Therapeutic (+10%) product categories. Constant currency organic growth was 3%, rising to 4% when excluding the February 2026 DualCap® divestiture — indicating underlying operational strength despite macro headwinds including tariffs. Management highlighted improved profitability, with Non-GAAP operating margin expanding 40 bps to 19.7%, and free cash flow up 26% to $24.7 million. The View Point Medical acquisition — closed April 1, 2026 for $140 million — is strategically targeted to expand Merit’s therapeutic oncology footprint with the differentiated OneMark® platform, expected to contribute margin-accretive growth. While full-year 2026 revenue guidance range remained unchanged ($1.612–$1.634B), it now incorporates modest incremental revenue ($2–4M) and $0.05 EPS dilution from the acquisition, reflecting disciplined integration planning. Notably, Merit reaffirmed its commitment to the final year of its Continued Growth Initiatives Program, emphasizing stable constant currency growth, improving profitability, and robust free cash flow generation as core priorities. The company also disclosed continued execution on portfolio optimization, having exited the non-core DualCap® business and advanced integration of multiple recent acquisitions including Biolife (May 2025), C2 CryoBalloon (Nov 2025), Cook Medical (Nov 2024), and EndoGastric Solutions (Jul 2024). These actions collectively signal an ongoing strategic pivot toward higher-margin, clinically differentiated therapeutic offerings within interventional medicine.